The FDA approved the drug Rasonque for the treatment of what TYPE OF CANCER, whose typically late diagnosis gives it a high mortality rate? The drug, which shuts off the KRAS gene mutation involved in 90 percent of cases, doubled survival time for participants in a late-stage clinical trial.
pancreatic cancer